Interim Report for the period April – June 2026

Eisai forecast FY2026 Leqembi sales of JPY 143.5B (≈SEK 8.4B), implying 63% growth vs. the prior year. BioArctic also signed a research and collaboration agreement with Eli Lilly to explore a potential new treatment combining BioArctic’s BrainTransporter™ technology with an undisclosed Lilly drug candidate.

Analysis

The direct earnings lever is ESAIY, but the real signal is that this looks like a transition from launch skepticism to a more durable commercialization curve. The market should focus on whether Leqembi can convert prescription growth into operating leverage; the cost stack is still dominated by diagnosis, infusion, MRI, and safety-monitoring friction, so top-line acceleration does not automatically translate into margin expansion. Any upside should also spill into BIIB sentiment through the same Alzheimer’s commercial channel.

For BRCTF, the Lilly collaboration is more valuable as third-party validation of the BrainTransporter platform than as near-term revenue. In small-cap biotech, platform validation can rerate the stock even when the economics are modest, but only if the deal includes meaningful upfront cash or a clear path to additional indications. For LLY, this is strategically sensible but financially immaterial; the partnership matters more for pipeline optionality than for model changes.

Contrarian risk: this is still an execution story, not a clean demand breakout. If real-world uptake stalls because of diagnostic capacity, payer friction, or lingering safety concerns, the sales trajectory can flatten quickly over the next 1-3 quarters. Likewise, if the Lilly agreement is mostly exploratory research, the market may overpay for optionality today and give it back once the lack of disclosed economics becomes obvious.

Key Decisions for Investors

• Long ESAIY on pullbacks over the next 1-3 months; use the sales guidance as a catalyst, but exit if quarterly Leqembi growth decelerates below a ~15-20% QoQ run-rate or reimbursement/safety headlines re-emerge.
• Fade any gap-up in LLY; the partnership is strategically positive but too small to move near-term EPS, so strength should be treated as sentiment rather than fundamentals.
• BRCTF is a watchlist, not a core position, until the economics of the Lilly deal are disclosed; if an upfront payment or milestone package is meaningful, consider a small speculative long with a 60-day catalyst window.
• For a cleaner relative-value expression, consider long ESAIY vs short XBI to isolate Alzheimer’s commercialization upside from broader biotech beta.